Purpose: This paper discusses the lack of complete selectivity in the photodynamic closure of choroidal neovasculature (CNV) associated with age-related macular degeneration. The arguments presented are supported by examples of clinical observations and may be useful for the design of the next generation of photosensitizers.
Results And Conclusion: Based on worldwide patient follow-up, it can be concluded that a substantial number of the more than 200000 treatments that have been dispensed so far could have resulted in stabilization of the disease for at least a number of years. Clinical observations also indicate that, in addition to the effective closure of the CNV observed 1 week after PDT, a significant closure (or at least reduced leakage) of normal choriocapillaries is observed in the treated area. Some of the concepts associated with the selectivity of Visudyne photodynamic therapy of choroidal neovascularization in age-related macular degeneration are also discussed.
Discussion: Novel approaches to improving selectivity could include attaching a photosensitizer to a targeting moiety such as a monoclonal antibody or a peptide. The undesirable closure of normal choriocapillaries in the treated area is one area of possible improvement to be sought for the next generation of drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0181-5512(04)96097-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravitreal AAV-IKV Mediated Delivery of Decorin Inhibits Choroidal Neovascularization, Fibrosis, Inflammation and Elevates Autophagy.
Exp Eye Res
January 2025
Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111. Electronic address:
Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. The exudative or wet form of AMD is caused by choroidal neovascularization (CNV) and subsequently a macular edema. Wet AMD can be effectively treated with anti-vascular endothelial growth factor (VEGF) therapies.
View Article and Find Full Text PDFAge-related eye diseases and subsequent risk of mental disorders in older adults: A real-world multicenter study.
J Affect Disord
January 2025
Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea. Electronic address:
Background: The relationship between age-related eye diseases and the subsequent risk of dementia and depressive disorders remains inconsistent. Furthermore, the effects on anxiety disorders and sleep disorders have been underexplored. This study aims to comprehensively examine the impact of age-related eye diseases on common mental disorders in older adults, thereby enhancing our understanding of the mental health implications in these conditions.
View Article and Find Full Text PDFLonger recreational screen time contributes to the risk of age-related macular degeneration: a UK Biobank cohort study and two-sample Mendelian randomisation.
J Glob Health
January 2025
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Recreational screen time (RST) has been found to be associated with cognitive decline and neurodegenerative diseases. However, the association between RST and age-related macular degeneration (AMD), an ocular neurodegenerative disease, is still unclear. We aimed to elucidate the association between RST and AMD.
View Article and Find Full Text PDFFrom pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.
Eye (Lond)
January 2025
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy.
Objective: To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart.
Methods: This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009-2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring.
Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases.
Adv Drug Deliv Rev
January 2025
Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel; Department of Molecular Genetics, Weizmann Institute of Science, 76100, Rehovot, Israel.
Self-renewal capacity and potential to differentiate into almost any cell type of the human body makes pluripotent stem cells a valuable starting material for manufacturing of clinical grade cell therapies. Neurodegenerative diseases are characterized by gradual loss of structure or function of neurons, often leading to neuronal death. This results in gradual decline of cognitive, motor, and physiological functions due to the degeneration of the central nervous systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!